SCHEMBL39930

SCHEMBL39930

NCCOCCOCCOCCC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.46
BLM P54132 3/20 0.46
TSHR P16473 3/20 0.46
THRB P10828 2/20 0.46
KMT2A Q03164 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
GABRR1 P24046 2/20 0.46
GABRR3 A8MPY1 1/20 0.46
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
HDAC3 O15379 1/20 0.46
GABBR2 O75899 1/20 0.46
CYP1A2 P05177 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRR2 P28476 1/20 0.46
SLC6A1 P30531 1/20 0.46
GABRA5 P31644 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL515661 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL515689 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL912891 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL23722964 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL561138 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL23515345 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL1578111 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL2723355 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL22777473 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A
SCHEMBL17932953 1.00 LMNA (0.46) LMNABLMTSHRTHRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US claimed
US-20250381277-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS DANA FARBER CANCER INST INC (US) 2025-12-18 US claimed
WO-2025242900-A1 COACERVATE-FORMING REAGENTS AND METHODS PARTITIONBIO LTD (GB) 2025-11-27 WO claimed
EP-4598585-A1 PRODUCT Oxford University Innovation Limited (GB) 2025-08-13 EP claimed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US claimed
WO-2025136225-A1 PROBES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2025-06-26 WO claimed
US-12320815-B2 Compositions and methods for enrichment and detection of ubiquitin and ubiquitin conjugates YALE UNIVERSITY (US) 2025-06-03 US claimed
US-20250099421-A1 Analgesic Therapeutics Based on conjugation of Biocompatible Polymers to Ion Channel Modulators Relevium Medical (IE) 2025-03-27 US claimed
CN-119212728-A Compositions and methods for treating neurological disorders 丹娜-法伯癌症研究院 2024-12-27 CN claimed
EP-4472670-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS Dana-Farber Cancer Institute, Inc. (US) 2024-12-11 EP claimed
WO-2023150552-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-10 WO claimed
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2023-04-13 US claimed
US-20220372022-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2022-11-24 US claimed
EP-4011904-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF Bayer Aktiengesellschaft (DE) 2022-06-15 EP claimed
WO-2022096394-A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-05-12 WO claimed
EP-3599245-A1 IL-17A BINDING POLYPEPTIDES AND MEDICAL USES THEREOF Dompé farmaceutici S.p.A. (IT) 2020-01-29 EP claimed
EP-2547355-B1 TFPI INHIBITORS AND METHODS OF USE Baxalta GmbH (CH) 2017-01-11 EP claimed
EP-2470672-A1 COMPOUND The Queen's University of Belfast (GB) 2012-07-04 EP claimed
US-20120156691-A1 COMPOUND QUEEN'S UNIVERSITY OF BELFAST 2012-06-21 US claimed
WO-2011024006-A1 COMPOUND QUEEN'S UNIVERSITY OF BELFAST (GB) 2011-03-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM LMNA 4762/4885BLM 3782/4885TSHR 1283/4885
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF TST, ABAT, AADAC LMNA 4387/4885BLM 4137/4885TSHR 255/4885
US-20220372022-A1 COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS DNPEP, NPEPPS, PAM LMNA 4762/4885BLM 3782/4885TSHR 1283/4885
US-12320815-B2 Compositions and methods for enrichment and detection of ubiquitin and ubiquitin conjugates STUB1, UBE3A, UBQLN1 LMNA 1301/4885BLM 917/4885TSHR 4537/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT LMNA 4184/4885BLM 4297/4885TSHR 17/4885
US-20120156691-A1 COMPOUND DNPEP, TMPRSS15, PEPD LMNA 2269/4885BLM 3222/4885TSHR 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.